Cancer52 responded to the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice consultation that ran in early 2024. As an alliance organisation for over 110 cancer charities Cancer52 recognises the many benefits that can be realised through the charity and pharmaceutical industry working together.
In the response, Cancer52 acknowledged the importance of a code of practice to enable transparency in all partnership working and called for greater consistency in collaborative approaches across the pharmaceutical sector.
The consultation closed on 29th February 2024, see more information.
Comments